SEC Form 4 · accession 0000899243-18-019983
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ted W Love
Officer — See Remarks · Director
Period of report
Jul 16, 2018
Accepted (ET)
Jul 17, 2018 · 9:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 16, 2018 | M | 12,194 | $16.40 | A | 1,117,979 | D | |
| Common Stock | holding | — | — | — | 2,500 | I | By Daughter | |
| Common Stock | holding | — | — | — | 2,500 | I | By Daughter |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $16.40 | Jul 16, 2018 | M | 12,194 | D | — | — | Common Stock | 12,194 | 132,806 | D |
Explanation of responses
- F1The shares underlying the option vest in equal quarterly installments over 16 quarters from January 17, 2017, subject to the Reporting Person's continued employment with the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Remarks
Chief Executive Officer and President